tiprankstipranks
Trending News
More News >

Lipella Pharmaceuticals Announces Nasdaq Delisting

Story Highlights
  • Lipella Pharmaceuticals was delisted from Nasdaq due to listing rule non-compliance.
  • The company plans to relist on a national exchange and continues its clinical programs.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Lipella Pharmaceuticals Announces Nasdaq Delisting

Don’t Miss TipRanks’ Half-Year Sale

Lipella Pharmaceuticals, Inc. ( (LIPO) ) has shared an announcement.

On June 25, 2025, Lipella Pharmaceuticals announced its delisting from the Nasdaq Capital Market due to non-compliance with certain listing rules related to private placement transactions. Despite this setback, the company remains committed to relisting on a national exchange and continues its clinical programs unaffected. Lipella’s shares are currently traded on the OTC Pink Market, and the company is actively exploring relisting options to align with its strategic goals and deliver long-term value to stockholders.

The most recent analyst rating on (LIPO) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Lipella Pharmaceuticals, Inc. stock, see the LIPO Stock Forecast page.

More about Lipella Pharmaceuticals, Inc.

Lipella Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on developing therapies for unmet medical needs. The company is advancing clinical programs for conditions such as oral lichen planus and hemorrhagic cystitis, supported by its in-house chemistry, manufacturing, and controls capabilities.

Average Trading Volume: 88,776

Technical Sentiment Signal: Sell

Current Market Cap: $4.91M

Find detailed analytics on LIPO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1